The goals of the Genetic Epidemiology and Risk Assessment (GERA) Program are to: 1) Utilize the tremendous advances in genetics and molecular biology in order to understand genetic, environmental, and gene-environment interactions in the etiology of cancer in human populations;2) Utilize these same advances in order to understand the molecular epidemiology of cancer prognosis and survivorship;and 3) Develop and apply novel statistical and informatics methods for the design and analysis of genetic and molecular epidemiology studies. Our cancer etiology studies use family-based, case-control and cohort study designs and focus on the genetic epidemiology of cancer, premalignant conditions, and intermediate phenotypes, as well as non-genetic risk factors and descriptive epidemiology. We are also addressing etiologic heterogeneity based on tumor phenotype. Our cancer prognosis research focuses on host factors, including genetic and serum biomarkers as well as lifestyle factors that influence prognosis;tumor biomarkers;and survivorship. Novel methods for the design and analysis of genetic and molecular epidemiologic studies are being developed, building on our expertise in biostatistics, medical informatics and bioinformatics. To achieve these goals we have assembled a team of 32 multidisciplinary investigators from over 10 divisions or departments. Total peer-reviewed funding is $8.81 M from 32.6 assigned grants, with 71% coming from the National Cancer Institute. Since 2008, the program has generated 622 publications, 43% reflecting intra-programmatic collaborations and 61% reflecting inter-programmatic collaborations. Notable contributions have been made in the epidemiology of pancreatic, lung, ovarian, breast, colon, lymphoma, and mammographic breast density, as well as to the statistical genetics and medical and bioinformatics literature. Leadership of the program is provided by Drs. Cerhan and Parker. The program makes extensive use of shared facilities. In the next 5 years, we will continue our innovative research in cancer etiology and prognosis with a focus on genomics, development and application of novel technologies and methods, and translation to the clinic and population as well as back to the lab to inform biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682941
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$402,631
Indirect Cost
$149,608
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:

Showing the most recent 10 out of 1086 publications